Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Current Liabilities data on file, last reported at $19.7 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $19.7 million, down 30.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.7 million (down 30.95% YoY), and the FY2025 annual result was $25.4 million, down 17.09% from the prior year.
• Total Current Liabilities slipped to $19.7 million in Q1 2026 per CRBU's latest filing, from $25.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $34.4 million in Q2 2023 and troughed at $19.7 million in Q1 2026.
• A 5-year average of $28.2 million and a median of $28.5 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities surged 30.88% in 2024, then plunged 30.95% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $28.1 million in 2022, then grew by 0.62% to $28.3 million in 2023, then increased by 8.3% to $30.7 million in 2024, then retreated by 17.09% to $25.4 million in 2025, then decreased by 22.59% to $19.7 million in 2026.
• Business Quant data shows CRBU's Total Current Liabilities at $19.7 million in Q1 2026, $25.4 million in Q4 2025, and $28.1 million in Q3 2025.